At week @ , similar proportions of patients receiving placebo ( @ % ) , apremilast @ mg twice a day ( @ % ) , and apremilast @ mg twice a day ( @ % ) met the American College of Rheumatology criteria for @ % improvement in disease activity ( the primary efficacy end point ) .